HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gossage, A. A. R. Articles by Himsworth, R. L. Search for Related Content PubMed PubMed Citation Articles by Gossage, A. A. R. Articles by Himsworth, R. L.

Graves' Disease: Thyroid Function and Immunologic Activity

Clinical Research Centre, Harrow, Middlesex, HA 1 3UJ, UK

Correspondence: For reprints contact: A. A. R. Gossage, Clinical Sciences Centre, Northern General Hospital, Shefield 5, UK.

ABSTRACT

Patients with Graves' were studied for two years during and after a twelve-month course of treatment. Disease activity was determined by repeated measurements of thyroidal uptake of [^99mTc]pertechnetate during tri-iodothyronine administration. These in-vivo measurements of thyroid stimulation were compared with the results of in-vitro assays of Graves, immunoglobulin (TSH binding inhibitory activity—TBIA). There was no correlation between the thyroid uptake and TBIA on diagnosis. Pertechnetate uptake and TBIA both declined during the twelved months of antithyroid therapy. TBIA was detectable in sera from 19 of the 27 patients diagnosis; in 11 of these 19 patients there was a good correlation (p <0.05) throughout the course of their disease between the laboratory assay of the Graves, immunoglobulin and the thyroid uptake. Probability of recurrence can be assessed but sustained remission of Graves disease after treatment cannot be predicted from either measurement alone or in combination.

This article has been cited by other articles:

				T. F. Davies Thyroid-Stimulating Antibodies Predict Hyperthyroidisma J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3777 - 3781. [Full Text]